Skip to main content

Day: August 22, 2022

ObsEva Receives Nasdaq Non-Compliance Notice

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange   Geneva, Switzerland and Boston, MA – August 22, 2022 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing novel therapies to improve women’s reproductive health, today announced that on August 19, 2022 it received a notification letter from The Nasdaq Stock Market (“Nasdaq”) advising the Company that it was not in compliance with Listing Rule 5450(b)(1)(A) requiring companies listed on the Nasdaq Global Select Market to maintain a minimum of $10,000,000 in stockholders’ equity for continued listing. The notification letter from Nasdaq was based on the Company’s Form 6-K dated August 17, 2022, disclosing financial information for the period ended June 30, 2022, which reported shareholders’ equity of ($2,103,000). Under Nasdaq rules the Company...

Continue reading

REC Silicon – REC Silicon and Mississippi Silicon Announce MOU for Solar Supply Chain Expansion

Moses Lake, Washington USA August 22, 2022: The passage of the Inflation Reduction Act which includes SEMA legislation will drive increases in the U.S. production of polysilicon and metallurgical grade silicon. REC Silicon and Mississippi Silicon today announce a Memorandum of Understanding committing the companies to negotiate a raw material supply agreement and help establish a low-carbon and fully traceable U.S.-based solar supply chain. Recent investment by the Hanwha Group into REC Silicon, in conjunction with Hanwha’s subsidiary Qcells, moves REC to expand its relationship with Mississippi Silicon to support the development of an end-to-end U.S. solar supply chain from raw silicon, to polysilicon, and finally fully assembled modules. Passage of Senator Jon Ossoff’s Solar Energy Manufacturing for America Act as part of a broad clean...

Continue reading

Santhera and ReveraGen Announce First Participant Dosed in FDA-funded Phase 2 Pilot Study with Vamorolone in Becker Muscular Dystrophy

Pratteln, Switzerland, and Rockville, MD, USA, August 22, 2022 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce that the first patient has been dosed in a Phase 2 pilot study to assess vamorolone in Becker muscular dystrophy (BMD), funded by the U.S. Food and Drug Administration (FDA). This Phase 2 pilot study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and exploratory clinical efficacy on motor function outcomes of vamorolone compared to placebo over a treatment period of 24 weeks in 39 males (aged ≥18 and

Continue reading

Kinarus Therapeutics to hold webinar on a new approach to treating COVID-19

KIN001 has synergistic antiviral, anti-inflammatory activity, and anti-fibrotic mechanisms Phase 2 trials of KIN001 in hospitalized and ambulatory COVID-19 patients ongoing Interim data from Phase 2 study in hospitalized COVID-19 patients expected end of Q3 Webinar on Aug 24 starts at 2:00 pm CET (8:00 am ET)Basel, Switzerland, 22 August 2022 — Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, today announced it will host a virtual event on the use of KIN001 for the treatment of COVID-19 on Wednesday, August 24 at 2:00 pm CET. The webinar will feature a presentation by Dr. Thierry Fumeaux M.D., MBA, Chief Medical Officer of Kinarus and former Chairman of the Swiss National COVID-19 Scientific Task...

Continue reading

Nykode Therapeutics to announce financial results for the first half of 2022 and host webcast presentation on August 24, 2022

OSLO, Norway, Aug. 22, 2022 (GLOBE NEWSWIRE) — Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced it will report its financial results for the first half of 2022 on August 24, 2022 before market open and subsequently host a webcast presentation at 4 p.m. CET / 10 a.m. ET. A live and archived webcast of the presentation can be accessed in the Investors section of the Company’s website: https://nykode.com/investors/financial-reports-and-presentations/. About Nykode TherapeuticsNykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies for the treatment of cancer and infectious diseases. Nykode’s modular vaccine technology specifically targets antigens...

Continue reading

MSP Recovery, Which Also Powers LifeWallet, Announces it Has Grown From Eleven Thousand (11,000) Unique Healthcare Member Lives in 2014, to More Than 34 Million Unique Healthcare Member Lives, as Well as Significant Advancements in Its Technological Capabilities, Including the Development of Cutting-Edge Blockchain Technology

CORAL GABLES, Fla., Aug. 22, 2022 (GLOBE NEWSWIRE) — MSP Recovery, Inc. (NASDAQ: MSPR) (“MSP Recovery” or the “Company”), a Medicare, Medicaid, commercial, and secondary payer reimbursement recovery and technology leader, today provided a business update.MSP Recovery, which powers LifeWallet, has grown from an initial eleven thousand (11,000) unique healthcare member lives in 2014, to more than 34 million unique healthcare member lives as of August 11, 2022, with an additional 3 million anticipated prior to September 30, 2022. MSP Recovery, in partnership with Tokenology, has completed development of cutting edge blockchain technology designed to solve significant problems the healthcare industry faces today, including fraud, inefficiency in payments, and antiquated processes, to provide real-time decentralized services that...

Continue reading

WTW appoints Sean Deehan as Leader of Hong Kong and Macau

HONG KONG, Aug. 21, 2022 (GLOBE NEWSWIRE) — WTW (NASDAQ: WTW), a leading global advisory, broking and solutions company, today announced the appointment of Sean Deehan as Leader for Hong Kong and Macau, effective 1 September 2022. Sean will also continue in his current position as Hong Kong Market Leader for WTW’s Insurance Consulting & Technology (ICT) business. Sean brings with him 25 years of life insurance, health insurance and pensions experience, including more than 10 years working in Mainland China and Hong Kong. He joined WTW in January last year to develop and grow the ICT business in Hong Kong. Commenting on the appointment, Clare Muhiudeen, Head of Asia, WTW, said: “Hong Kong remains a major international financial centre in Asia, a gateway to and from Mainland China and a key market in our Greater Bay Area growth...

Continue reading

FY Financial Results Webinar

Perth, Aug. 22, 2022 (GLOBE NEWSWIRE) — FY22 RESULTS INVESTOR WEBINAR / CALL Perth, Western Australia/August 22, 2022/ Perseus Mining Limited (ASX/TSX: PRU) is hosting an investor webinar and conference call to discuss its FY22 Financial Results, which are anticipated for release around 8:30am AEST on Wednesday August 31, 2022. CALL DETAILSAustralia: Wednesday August 31, 2022 Perth – 7:00am Sydney/Melbourne – 9:00am Canada: Tuesday August 30, 2022 Toronto – 7:00pm Vancouver – 4:00pm UK: Wednesday August 31, 2022 London – 12:00amRegister for the investor webinar at the link below: https://us02web.zoom.us/webinar/register/WN_wbqsUTe-Q5GHiDXj5ucBhA After registering, you will receive a confirmation email containing information about joining the webinar. To join the webinar via telephone, please use one of the following numbers...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.